FDA Fast-Tracks Review of 3 New Immunotherapy Options for Esophageal Cancer Patients
The U.S. Food & Drug Administration has granted Priority Review for the use of immunotherapies in three new designations for [...]
New Treatment Option for Patients with HER2+ Gastroesophageal Junction Adenocarcinoma
The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic HER2+ [...]
Latest US Stats Show More Esophageal Cancer Cases, Fewer Deaths
The latest statistics released by the American Cancer Society projects that fewer Americans will die of Esophageal Cancer in 2021 [...]
Groundbreaking Immunotherapy Studies in Esophageal Cancer show Significant Benefits
Findings of three studies important to Esophageal Cancer patients were presented at the 2020 ESMO (European Society of Medical Oncology) [...]
Personalized Approach Shows Survival Benefit in Esophageal Adenocarcinoma
Results of a clinical study called PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) found survival benefits for patients when compared to [...]
Immunotherapy Breakthroughs for Esophageal Cancer Patients
The early results of two large, Phase III clinical trials of the immunotherapy Opdivo (nivolumab) showed significant survival benefits for [...]
Barrett’s Esophagus and Esophageal Adenocarcinoma can run in Families
The familial connection is one of the Strongest Indicators of Risk according to Experts. ECAN spoke with the Leading Researcher [...]
FDA calls New Screening Test Using DNA to Detect Esophageal Cancer a Breakthrough Device
First Time the FDA has given Breakthrough Designation for a Device Targeting Diseases of the Esophagus. Lucid Diagnostics' EsoGuard™ Esophageal [...]
FDA Approves First Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma
The U.S. Food and Drug Administration has approved Keytruda (Pembrolizumab) for treatment of advanced Esophageal Squamous Cell Carcinoma (ESCC). It [...]
First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Cancer
First Esophageal Cancer patient is dosed in Phase 3 clinical trial using immune checkpoint inhibitor Tyvyt (sintilimab injection), in [...]